Table 2.
Intercohort univariate analysis.
| Baseline | Grouped By final CRT | Grouped By final VA change | Grouped By injection times | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Clinical data | < 300 μm | ≥ 300 μm | Improved | Not improved | ≤ 6 shots | > 6 shots | |||
| Age (years) | 57.64 ± 11.66 | 64.48 ± 7.63 | p < 0.05† | 60.85 ± 9.19 | 58.82 ± 14.45 | NS | 59.30 ± 13.14 | 61.05 ± 8.71 | NS |
| Gender (Female) | 20/39 (51.3%) | 9/25 (36.0%) | NS | 21/47 (44.7%) | 8/17 (47.1%) | NS | 12/27 (44.4%) | 17/37 (45.9%) | NS |
| HbA1c (%) | 7.47 ± 1.03 | 7.40 ± 1.02 | NS | 7.47 ± 0.92 | 7.37 ±1.29 | NS | 7.24 ± 0.98 | 7.59 ± 1.04 | NS |
| CRT (μm) | 392.76 ± 108.58 | 445.47 ± 119.24 | p < 0.05† | 421.36 ± 118.39 | 384.72 ± 101.42 | NS | 366.58 ± 86.84 | 434.40 ± 120.87 | p < 0.05† |
| LogMAR | 0.59 ± 0.37 | 0.55 ± 0.33 | NS | 0.63 ± 0.36 | 0.42 ± 0.29 | p < 0.05 | 0.47 ± 0.30 | 0.63 ± 0.37 | p < 0.05† |
| DR staging/OCT Biomarkers | |||||||||
| Mild NPDR | 3/59 (5.08%) | 1/32 (3.13%) | NS | 1/66 (1.52%) | 3/25 (12.0%) | p < 0.05 | 3/31 (9.68%) | 1/60 (1.67%) | NS |
| Moderate NPDR | 9/59 (15.3%) | 5/32 (15.6%) | NS | 11/66 (16.7%) | 3/25 (12.0%) | NS | 5/31 (16.1%) | 9/60 (15.0%) | NS |
| Severe NPDR | 16/59 (27.1%) | 12/32 (37.5%) | NS | 25/66 (37.9%) | 3/25 (12.0%) | p < 0.05 | 7/31 (22.6%) | 21/60 (35.0%) | NS |
| PDR | 3/59 (5.08%) | 3/32 (9.38%) | NS | 4/66 (6.06%) | 2/25 (8.00%) | NS | 2/31 (6.45%) | 4/60 (6.67%) | NS |
| PDR s/p PRP | 28/59 (47.5%) | 11/32 (34.4%) | NS | 25/66 (37.9%) | 14/25 (56.0%) | NS | 14/31 (45.2%) | 25/60 (41.7%) | NS |
| SRF (+) | 14/59 (23.7%) | 4/32 (12.5%) | NS | 13/66 (19.7%) | 5/25 (20.0%) | NS | 4/31 (12.9%) | 14/60 (23.3%) | NS |
| IRC (+) | 45/59 (76.3%) | 26/32 (81.3%) | NS | 54/66 (81.8%) | 17/25 (68.0%) | NS | 25/31 (80.6%) | 46/60 (76.7%) | NS |
| ERM (+) | 10/59 (16.9%) | 13/32 (40.6%) | p < 0.05† | 21/66 (31.8%) | 2/25 (8.00%) | p < 0.05† | 5/31 (16.1%) | 18/60 (30.0%) | NS |
| EZD (+) | 21/59 (35.6%) | 5/32 (15.6%) | p < 0.05† | 24/66 (36.4%) | 2/25 (8.00%) | p < 0.05† | 7/31 (22.6%) | 19/60 (31.7%) | NS |
| DRIL (+) | 20/59 (33.9%) | 11/32 (34.4%) | NS | 23/66 (34.8%) | 8/25 (32.0%) | NS | 9/31 (29.0%) | 22/60 (36.7%) | NS |
| HE (+) | 45/59 (76.3%) | 25/32 (78.1%) | NS | 53/66 (80.3%) | 17/25 (68.0%) | NS | 23/31 (74.2%) | 47/60 (78.3%) | NS |
CRT, Central Retinal Thickness; DR, Diabetic Retinopathy; NPDR, Non Proliferative Diabetic Retinopathy; PDR, Proliferative Diabetic Retinopathy; PRP, Panretinal Photocoagulation; SRF, Subretinal Fluid; IRC, Intra-Retinal Cyst; ERM, Epiretinal Membrane; EZD, Ellipsoid Zone Disruption; DRIL, Disorganization of Retinal Inner Layers; HE, Hard Exudate. N: Indicates a non-statistically significant.
†
Indicates that statistical significance in this univariate analysis was also confirmed in multivariate analysis in Table 3. The bold values indicate p < 0.05.